Caers J., Vande Broek I., De Raeve H., Michaux L., Trullemans F., Schots R., Van Camp B., Vanderkerken K., Multiple myelomaan update on diagnosis and treatment European Journal of Haematology 2008 81 5 329 343
Galmarini C. M., Popowycz F., Joseph B., Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy Current Medicinal Chemistry 2008 15 11 1072 1082
Kicska G. A., Long L., Hrig H., Fairchild C., Tyler P. C., Furneaux R. H., Schramm V. L., Kaufman H. L., Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes Proceedings of the National Academy of Sciences of the United States of America 2001 98 8 4593 4598
Bantia S., Miller P. J., Parker C. D., Ananth S. L., Horn L. L., Kilpatrick J. M., Morris P. E., Hutchison T. L., Montgomery J. A., Sandhu J. S., Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)a novel potent and orally active immunosuppressive agent International Immunopharmacology 2001 1 6 1199 1210
Bantia S., Ananth S. L., Parker C. D., Horn L. L., Upshaw R., Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitorBCX-1777 International Immunopharmacology 2003 3 6 879 887
Balakrishnan K., Nimmanapalli R., Ravandi F., Keating M. J., Gandhi V., Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells Blood 2006 108 7 2392 2398
Alonso R., Lpez-Guerra M., Upshaw R., Bantia S., Smal C., Bontemps F., Manz C., Mehrling T., Villamor N., Campo E., Montserrat E., Colomer D., Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM Blood 2009 114 8 1563 1575
Kuroda J., Taniwaki M., Involvement of BH3-only proteins in hematologic malignancies Critical Reviews in Oncology/Hematology 2009 71 2 89 101
Homminga I., Zwaan C. M., Manz C. Y., Bantia S., Parker C., Buijs-Gladdines J., Smits W., Horstmann M. A., Pieters R., Meijerink J. P. P., In-vitro efficacy of the deoxyguanoside analogs forodesine (BCX-1777) and ARA-G in pediatric acute lymphoblastic leukemia ASH Annual Meeting Abstracts 2009 114 22 2038
Duvic M., Forero-Torres A., Foss F., Oral forodesine (Bcx-1777) is clinically active in refractory cutaneous T-cell lymphoma: results of a phase I/II study Blood 2006 108 11 698a
Duvic M., Foss F., Olsen E., Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma Blood 2004 104 11 683a
Furman R. R., Gandhi W., Bennett J. C., Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I/II studies in patients with B-cell acute lymphoblastic leukemia Blood 2004 104 11 750a
Furman R. R., Iosava G., Isola L., Forodesine (FodosineTM), a PNP inhibitor active in relapsed or refractory T-cell leukemia patients(phase II study) Blood 2005 106 11 259a
Gandhi V., Kilpatrick J. M., Plunkett W., Ayres M., Harman L., Du M., Bantia S., Davisson J., Wierda W. G., Faderl S., Kantarjian H., Thomas D., A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine) Blood 2005 106 13 4253 4260
Robak T., Korycka A., Ewa L.-M., Robak P., Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases Molecules 2009 14 3 1183 1226
Robak T., Korycka A., Kasznicki M., Wrzesien-Kus A., Smolewski P., Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications Current Cancer Drug Targets 2005 5 6 421 444
Kraut E. H., Crowley J. J., Grever M. R., Keppen M. D., Bonnet J. D., Hynes H. E., Salmon S. E., Phase II study of fludarabine phosphate in multiple myeloma. A Southwest oncology group study Investigational New Drugs 1990 8 2 199 200
Dimopoulos M. A., Kantarjian H. M., Estey E. H., Alexanian R., 2-Chlorodeoxyadenosine in the treatment of multiple myeloma Blood 1992 80 6 1626
Bjrkstrand B., Rasmussen T., Remes K., Gruber A., Pelliniemi T.-T., Johnsen H. E., Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study European Journal of Haematology 2003 70 6 379 383
Asosingh K., Radl J., Van Riet I., Van Camp B., Vanderkerken K., The 5TMM series: a useful in vivo mouse model of human multiple myeloma Hematology Journal 2000 1 5 351 356
Asosingh K., De Raeve H., Croucher P., Goes E., Van Riet I., Van Camp B., Vanderkerken K., In vivo homing and differentiation characteristics of mature (CD45 -) and immature (CD45 +) 5T multiple myeloma cells Experimental Hematology 2001 29 1 77 84
Pickering J. W., Gelder F. B., A human myeloma cell line that does not express immunoglobulin but yields a high frequency of antibody-secreting hybridomas Journal of Immunology 1982 129 1 406 412
Srivastava B. I. S., Minowada J., Terminal deoxynucleotidyl transferase activity in a cell line (Molt-4) derived from the peripheral blood of a patient with acute lymphoblastic leukemia Biochemical and Biophysical Research Communications 1973 51 3 529 535
Menu E., Garcia J., Huang X., Di Liberto M., Toogood P. L., Chen I., Vanderkerken K., Chen-Kiang S., A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model Cancer Research 2008 68 14 5519 5523
Menu E., Valckenborgh E. V., Camp B. V., Vanderkerken K., The role of the insulin-like growth factor 1 receptor axis in multiple myeloma Archives of Physiology and Biochemistry 2009 115 2 49 57
Chen-Kiang S., Cell-cycle control of plasma cell differentiation and tumorigenesis Immunological Reviews 2003 194 39 47
Jourdan M., Reme T., Goldschmidt H., Fiol G., Pantesco V., De Vos J., Rossi J.-F., Hose D., Klein B., Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells British Journal of Haematology 2009 145 1 45 58
Huang M., Wang Y., Gu J., Yang J., Noel K., Mitchell B. S., Schramm V. L., Graves L. M., Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H Leukemia Research 2008 32 8 1268 1278
